In this episode, Kathleen Moore, MD, MS, and Nicoletta Colombo, MD, PhD, provide expert insights on key updates and new clinical trial data presented at the 2023 ASCO Annual Meeting for cervical, endometrial, and ovarian cancers, including:
- ENGOT-EN6-NSGO/GOG-3031/RUBY: phase III study of dostarlimab plus chemotherapy followed by dostarlimab maintenance in primary advanced or recurrent endometrial cancer outcomes by BICR
- CCTG CX.5-SHAPE: phase III trial of radical hysterectomy and pelvic node dissection compared with simple hysterectomy and pelvic node dissection in low-risk, early-stage cervical cancer
- Final OS results from KEYNOTE-826: phase III study of CT with or without pembrolizumab as first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer
- DUO-O: a randomized, placebo-controlled phase III study of durvalumab plus carboplatin, paclitaxel, and bevacizumab and then maintenance bevacizumab, durvalumab, and olaparib in patients with newly diagnosed advanced ovarian cancer and no BRCA1/2 gene alteration
- MIRASOL: an initial report from a phase III study of mirvetuximab soravtansine vs investigator’s choice of CT in platinum-resistant ovarian cancer with high expression of FRα
- Patient-reported outcomes from the phase III ENGOT-EN6/RUBY trial of dostarlimab plus standard-of-care CT in primary advanced or recurrent endometrial cancer
Presenters:
Kathleen Moore, MD, MS
Associate Director, Clinical Research
Department of Gynecologic Oncology
Stephenson Cancer Center, University of Oklahoma
Oklahoma City, Oklahoma
Nicoletta Colombo, MD, PhD
Associate Professor of Obstetrics and Gynecology
European Institute of Oncology
University of Milan-Bicocca
Milan, Italy
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Merck Sharp & Dohme Corp., Novocure Inc., and Seagen Inc.
Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
